Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
30 avr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08 janv. 2024 08h00 HE
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
06 déc. 2023 16h08 HE
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size to Hit Around USD 2,517 Mn by 2032
27 mars 2023 02h27 HE
|
Market.Us
New York, March 27, 2023 (GLOBE NEWSWIRE) -- The global alpha-1 antitrypsin deficiency augmentation therapy market size accounted for USD 1,413 million in 2022 and growth is estimated to accelerate...
Global Alpha-1 Antitrypsin Deficiency (A1ATD) Treatment Market to Reach US$ 10 Billion by 2033; Growing at an Impressive 12.8% CAGR – Future Market Insights, Inc.
09 janv. 2023 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Jan. 09, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Alpha-1 Antitrypsin Deficiency market to augment at a 12.8% CAGR from 2023 to 2033. By the end of...
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel Therapeutic Assessment
12 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel...